icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Digital Experience
November 13 - 16 - 2020
Back grey_arrow_rt.gif
Safety and Efficacy of 24 Weeks of Treatment With Oral TLR8 Agonist Selgantolimod in Viremic Adult Patients With Chronic Hepatitis B: a Phase 2 Study
  AASLD 2020 Nov 11-16 virtual
Reported by Jules Levin
Harry L. Janssen,1 Young-Suk Lim,2 Hyung Joon Kim,3 Cheng-Hao Tseng,4 Carla S. Coffin,5 Magdy Elkashab,6 Sang Hoon Anh,7 Anh-Hoa Nguyen,8 Diana Chen,8 Jeffrey J. Wallin,8 Susanna K. Tan,8 Jenny C. Yang,8 Anuj Gaggar,8 Diana M. Brainard,8 Scott Fung,1 Yoon Jun Kim,9 Jia-Horng Kao,10 Wan-Long Chuang11
1Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; 2Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 3Chung-Ang University College of Medicine, Seoul; 4E-Da Hospital, Kaohsiung City, Taiwan; 5Cumming School of Medicine, University of Calgary, Alberta, Canada; 6Toronto Liver Centre, Toronto; 7Severance Hospital, Yonsei University College of Medicine, Seoul; 8Gilead Sciences, Inc., Foster City, CA; 9Seoul National University Hospital, Seoul; 10National Taiwan University Hospital, Taipei City, Taiwan; 11Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City








References: 1. Daffis S, et al. J Hepatol 2017;66:S694; 2. Brooks AE, et al. AASLD 2019, abstr 706; 3. Daffis S, et al. J Hepatol 2018;68:S800; 4. Micolochick-Steuer H, et al. Hepatology 2017;66:489A; 5. Gane E, et al. AASLD 2019, poster 697; 6. Gane E, et al. EASL 2020, abstr 71. Acknowledgments: We extend our thanks to the patients, their families, and all participating investigators. This study was funded by Gilead Sciences, Inc. Disclosures: H.L. Janssen, A.-H. Nguyen, D. Chen, J. Wallin, S.K. Tan, J.C. Yang, A. Gaggar, and D.M. Brainard: Gilead; Y.-S. Lim and S. Fung: nothing declared; H.J. Kim, C.-H. Tseng, C.S. Coffin, S.H. Ahn, Y.J. Kim, J.-H. Kao, and W.-L. Chuang: nothing to disclose; M. Elkashab: Gilead, AbbVie, Allergan, Assembly, BMS, Boehringer Ingelheim, Enanta, Genfit, Intercept, Janssen, Madrigal, MSD, Novartis, Novo Nordisk, Pfizer, Roche-Genentech, and Spring Bank.